Alise Reicin

Alise S.
Reicin currently works at Tectonic Therapeutic, Inc., as President, Chief Executive Officer & Director from 2020, Tectonic Operating Co., Inc., as President, Chief Executive Officer & Director from 2020, Sharsheret, Inc., as Director, Sana Biotechnology, Inc., as Independent Director from 2020, Immatics NV, as Non-Executive Director from 2024, and Israel Biotech Fund, as Venture Advisor.
Dr. Reicin also formerly worked at AVROBIO, Inc., as Chief Executive Officer & Director, Homology Medicines, Inc., as Independent Director, Celgene Corp., as President-Global Clinical Development from 2018 to 2019, Merck & Co., Inc., as VP-Oncology Program & Pipeline Leadership, and EMD Serono, Inc., as SVP & Head-Global Clinical Development from 2015 to 2018.
Dr. Reicin received her undergraduate degree in 1982 from Barnard College and doctorate degree in 1987 from Harvard Medical School.